Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia
about
Investigational drugs to treat methicillin-resistant Staphylococcus aureusWhere does a Staphylococcus aureus vaccine stand?Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaProgress towards recombinant anti-infective antibodies.Novel targeted immunotherapy approaches for staphylococcal infection.Why antibodies disobey the Hippocratic Oath and end up doing harm: a new clue.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Functional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy.Recombinant ESAT-6-like proteins provoke protective immune responses against invasive Staphylococcus aureus disease in a murine model.Active immunization with an octa-valent Staphylococcus aureus antigen mixture in models of S. aureus bacteremia and skin infection in miceAn evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children.Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis modelExploiting dominant-negative toxins to combat Staphylococcus aureus pathogenesisGlobal antibody response to Staphylococcus aureus live-cell vaccinationTargeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus DiseaseEsxA might as a virulence factor induce antibodies in patients with Staphylococcus aureus infection.Prevention and treatment of Staphylococcus aureus biofilms.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.Immune proteomics of Staphylococcus aureus.Challenges for a universal Staphylococcus aureus vaccine.Immunotherapy for infectious diseases in haematological immunocompromise.A human monoclonal antibody that specifically binds and inhibits the staphylococcal complement inhibitor protein SCIN.Prevention of Staphylococcus aureus Ventilator-Associated Pneumonia: Conventional Antibiotics Won't Cut It.Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.Infective endocarditis.Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection.
P2860
Q26780246-CBED39A9-E4C5-47F8-8BAC-29AFAB0AC6DDQ26828726-9DAC2CB7-7C85-4006-B468-B3585623C4F9Q29616084-46588E56-F86D-495A-8627-F3329B6FD3B2Q33568256-87740EB7-E567-464E-8EFE-500E2F88643BQ33910565-CE2413F0-6B38-42DF-AE55-59998707A33FQ34090255-845361D9-2DDF-48D6-8D98-B85457F09417Q34112608-06457F48-5090-4192-BBC3-E066210C0045Q34483544-5B01BD22-883B-48C8-9C81-8D0E0EF4EFE9Q34889865-312CB65A-33CE-4240-BE52-32230134C387Q35116935-035062C1-DBC2-4720-A3F4-252DC04EDA6DQ35618211-5AF638DA-2DDD-452A-86F1-A984EE2EDDAAQ35736907-C5C125E3-C12A-40BD-BA78-B205F46C3FFDQ36184397-CA4593BA-D3B2-4796-B5C5-422F7FF5E546Q36636170-96332B97-391E-42FF-9706-719FFC79D41FQ36824281-C62B55C3-F999-4569-929B-5140E3B22B03Q37075941-7FE70979-CADB-49C2-9561-ACE61378DCBAQ37244565-9273827D-C7D7-4C23-ABC3-6A52D70A0E70Q37482155-5ABC187E-9913-4811-BF88-1A8D315E1822Q37800939-FED3D1AD-2913-4C9B-B0FD-E7C3685DE0EAQ37895214-CDAA7EEE-DE00-4EA8-9EF8-9DC5FEF90066Q37987099-3AC01645-3A92-41BA-A926-F30FD3D4CD35Q39215653-7451B6B1-B4E7-4D84-8C2E-FD9BE454EEBDQ40301010-F1A6D780-0D13-4CAF-AC84-A4F05DDB5C6EQ40346731-82EE6B7A-3E1F-45EF-B68E-1FDDF31BEFB7Q40416064-C900D919-361B-4A42-8313-116BD1C6D8C2Q52943386-AA2070DE-EE95-43B4-B771-17300866B606Q55278118-8DC6CEB3-F87E-4E04-9BBC-4CE4BC735621
P2860
Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Phase II, randomized, multicen ...... aphylococcus aureus bacteremia
@ast
Phase II, randomized, multicen ...... aphylococcus aureus bacteremia
@en
type
label
Phase II, randomized, multicen ...... aphylococcus aureus bacteremia
@ast
Phase II, randomized, multicen ...... aphylococcus aureus bacteremia
@en
prefLabel
Phase II, randomized, multicen ...... aphylococcus aureus bacteremia
@ast
Phase II, randomized, multicen ...... aphylococcus aureus bacteremia
@en
P2093
P2860
P921
P356
P1476
Phase II, randomized, multicen ...... aphylococcus aureus bacteremia
@en
P2093
Christopher W Woods
Donald P Levine
H Preston Holley
Mark E Rupp
Naomi Veney
Peter V Dicpinigaitis
P2860
P304
P356
10.1128/AAC.00570-07
P407
P577
2007-09-24T00:00:00Z